Holen Sie sich die Stockscreener-App
322.46
0.76%
-2.47
Handel nachbörslich:
322.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$324.93
Offen:
$324.21
24-Stunden-Volumen:
1.19M
Relative Volume:
0.89
Marktkapitalisierung:
$62.73B
Einnahmen:
$325.78B
Nettoeinkommen (Verlust:
$1.64B
KGV:
38.79
EPS:
8.3139
Netto-Cashflow:
$3.61B
1W Leistung:
-0.72%
1M Leistung:
-10.87%
6M Leistung:
+2.66%
1J Leistung:
+17.73%
1-Tages-Spanne:
$319.72
$325.91
1-Wochen-Bereich:
$315.00
$325.91
52-Wochen-Spanne:
$271.00
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
322.46 | 63.21B | 325.78B | 1.64B | 3.61B | 8.3139 |
MCK
Mckesson Corporation
|
873.43 | 106.71B | 397.96B | 4.55B | 9.64B | 34.77 |
CAH
Cardinal Health Inc
|
215.80 | 50.62B | 244.67B | 1.68B | 5.51B | 6.9487 |
HSIC
Henry Schein Inc
|
75.62 | 8.67B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
2.26 | 1.96B | 14.85M | -136.07M | 7.23M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Is Cencora Inc stock a top performer YTD2026 Price Momentum & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Cencora to acquire EyeSouth retina business for $1.1 billion - MSN
Cencora Inc. stock rises Wednesday, still underperforms market - MarketWatch
Cencora (COR) Analyst Rating Update: Evercore ISI Group Lowers P - GuruFocus
Evercore ISI Adjusts Price Target on Cencora to $360 From $420, Maintains Outperform Rating - marketscreener.com
Is Cencora (COR) Pricing Reflect Its DCF Value After Recent Healthcare Supply Chain Scrutiny - simplywall.st
Daytona Street Capital LLC Takes Position in Cencora, Inc. $COR - MarketBeat
Here's Why You Should Hold Cencora Stock in Your Portfolio Now - MSN
Cencora CFO James Cleary to retire June 30, 2026 - MSN
Cencora to Acquire EyeSouth Retina Business for $1.1 Billion - MyChesCo
Cencora Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cencora, Inc. (COR) Stock forecasts - uk.finance.yahoo.com
Cencora, Inc. (COR) signs binding agreement to expand retina network with EyeSouth acquisition - MSN
Cencora Expands Retina Network As CFO Retirement Opens New Chapter - simplywall.st
Cencora (COR) SVP & CAO receives 3,936 restricted stock units - Stock Titan
HF Advisory Group LLC Boosts Stock Holdings in Cencora, Inc. $COR - MarketBeat
Cencora to Announce Fourth Quarter Fiscal 2025 Results on November 5 - MSN
Cencora Inc. Stock: Institutional Buying Signals Strength in Pharmaceutical Distribution Leader Amid - AD HOC NEWS
Press Release: Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release - Moomoo
Cencora, Inc. (COR) Options Chain - Yahoo! Finance Canada
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release - marketscreener.com
Cencora will post quarterly results before the market opens May 6 - Stock Titan
Deals tracker: Boston Scientific acquires Valencia Technologies - Modern Healthcare
Cencora CFO James Cleary to Retire June 30, 2026 - MyChesCo
Nisa Investment Advisors LLC Acquires 27,857 Shares of Cencora, Inc. $COR - MarketBeat
Bourgeon Capital Management LLC Invests $2.74 Million in Cencora, Inc. $COR - MarketBeat
Cencora Inc. stock rises Tuesday, still underperforms market - MarketWatch
Spire Wealth Management Raises Stock Position in Cencora, Inc. $COR - MarketBeat
Allspring Global Investments Holdings LLC Sells 40,638 Shares of Cencora, Inc. $COR - MarketBeat
Assessing Cencora (COR) Valuation After Recent Share Price Weakness And Premium P/E Ratio - simplywall.st
Cencora, Inc. (COR) Signs Binding Agreement to Expand Retina Network With EyeSouth Acquisition - Insider Monkey
Donaldson Capital Management LLC Has $46.31 Million Stock Holdings in Cencora, Inc. $COR - MarketBeat
Cencora, Inc. $COR Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Cencora, Inc. $COR Shares Sold by Waycross Partners LLC - MarketBeat
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
6,960 Shares in Cencora, Inc. $COR Acquired by Global X Japan Co. Ltd. - MarketBeat
Matrix Trust Co Invests $1.40 Million in Cencora, Inc. $COR - marketbeat.com
Synergy Asset Management LLC Cuts Stake in Cencora, Inc. $COR - MarketBeat
Vanguard discloses zero Cencora holdings (NYSE: COR) after internal realignment - Stock Titan
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Cencora to buy EyeSouth Partners' retina division in $1B deal - Eyes On Eyecare
Centene Corp stock faces Medicaid managed care pressures amid management uncertainty - AD HOC NEWS
Cencora Inc. stock faces uncertainty amid Medicaid managed care pressures and management shifts - AD HOC NEWS
Cencora (NYSE:COR) Advances Retina Focused Specialty Care Strategy Within S&P 500 - Kalkine Media
Pensionfund Sabic Makes New Investment in Cencora, Inc. $COR - MarketBeat
Cencora, Inc. $COR Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Cencora, Inc. $COR Shares Sold by Avanza Fonder AB - marketbeat.com
Cencora Expands Retina Network With EyeSouth Deal And Earnings Focus - simplywall.st
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):